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Ubiquitin-specific proteases (USPs) have in recent
years emerged as a promising therapeutic target
class. We identified selective small-molecule inhibi-
tors against a deubiquitinase complex, the human
USP1/UAF1, through quantitative high throughput
screening (qHTS) of a collection of bioactive mole-
cules. The top inhibitors, pimozide and GW7647,
inhibited USP1/UAF1 noncompetitively with a Ki of
0.5 and0.7mM, respectively, anddisplayedselectivity
against a number of deubiquitinases, deSUMOylase,
and cysteine proteases. The USP1/UAF1 inhibitors
act synergistically with cisplatin in inhibiting cis-
platin-resistant non-small cell lung cancer (NSCLC)
cell proliferation. USP1/UAF1 represents a promising
target fordrug interventionbecauseof its involvement
in translesion synthesis and Fanconi anemia path-
way important for normal DNA damage response.
Our results support USP1/UAF1 as a potential thera-
peutic target and provide an example of targeting
the USP/WD40 repeat protein complex for inhibitor
discovery.
INTRODUCTION
Abnormalities in the ubiquitin-mediated processes have been
linked tomanyhumandiseases, includingneurological disorders,
viral infection, and cancer. Ubiquitin is a versatile signaling mole-
cule. Although initially discovered in the context of proteasome-
mediated protein degradation, ubiquitin and ubiquitin-like pro-
teins are now known to play important roles in amyriad of cellular
processes, including membrane trafficking, transcription regula-
tion, and DNA damage response (Kirkin and Dikic, 2007).
In recent years, the ubiquitin-proteasome system has
attracted increasing attention as a target for novel therapeutic
approaches. A series of proteasome inhibitors has been devel-
oped and tested in both cell and animal models (Adams, 2004;
Kisselev and Goldberg, 2001). In 2003, the proteasome inhibitor
bortezomib (Velcade) was approved by FDA for the treatment
of multiple myeloma and later for mantle cell lymphoma. The1390 Chemistry & Biology 18, 1390–1400, November 23, 2011 ª2011success of Velcade has established the ubiquitin-proteasome
system as a valid target for anti-cancer treatment. However, pro-
teasome inhibitors in general suffer from a narrow therapeutic
index because the proteasome is at a convergence point down-
stream of many important cellular pathways (Gue´dat and Col-
land, 2007). A promising alternative to proteasome inhibitor is
to target the enzymes upstream of proteasome-mediated
protein degradation, i.e., the ubiquitin conjugation and deconju-
gation system, to generate more specific, less toxic therapeutic
agents.
Deubiquitinases (DUBs) are a class of enzymes that cleave the
isopeptide bond formed between the C-terminal carboxylate of
ubiquitin and a lysine side-chain amino group on the target
protein. Besides cleaving the free polyubiquitin chain bearing
different linkages, DUB can also remove a single ubiquitin moiety
or ubiquitin chain from a target protein (Amerik and Hoch-
strasser, 2004; Reyes-Turcu et al., 2009). The human genome
encodes close to 100 DUBs. DUBs can be classified into five
families and ubiquitin-specific proteases (USPs) constitute the
largest DUB family (Nijman et al., 2005b). Human USPs are
emerging as promising targets for pharmacological intervention.
The advantage of inhibiting USPs lies in the potential specificity
of therapeutic intervention that can lead to better efficacy and
reduce nonspecific side effects.
Close to 60 USPs were identified in humans. However, only
a few small-molecule inhibitors have been reported targeting
human USPs. Colland et al. (2009) identified a cyano-indenopyr-
azine derivative that inhibits USP7 with a submicromolar IC50.
This compound inhibited deubiquitination of p53 both in vitro
and in vivo. Tian et al. (2011) reported another USP7 inhibitor
with IC50 of 7.8–8.6 mM. Lee et al. (2010) recently reported
a USP14 inhibitor with a 4–5 mM IC50, that accelerates protein
degradation by inhibiting the proteasome-associated USP14
activity in a reconstituted assay and in mouse embryonic fibro-
blast cells.
Among the human USPs, USP1 occupies a special position as
it is implicated in DNA damage response. Previous studies
showed that disruption of USP1 in chicken DT40 cells resulted
in increased sensitivity to DNA crosslinkers (Oestergaard et al.,
2007). Knockout of the murine USP1 gene in a mouse model
resulted in hypersensitivity to mitomycin C (Kim et al., 2009).
These observations suggest that inhibiting the cellular activity
of USP1 may sensitize cells to DNA crosslinking agents. USP1Elsevier Ltd All rights reserved
Figure 1. qHTS against Human USP1/UAF1
(A) Schematic representation of the USP1/UAF1-catalyzed hydrolysis of
ubiquitin-rhodamine110-glycine substrate.
(B) Heat maps illustrating the 1536-well plate activity of one representative
compound library that was screened from low to high concentrations (left to
right) with each plate containing a different compound concentration. The
percent activity is depicted as a gradient of color where white, blue, and
red indicate no, increasing, and decreasing activity, respectively, relative
to no-inhibitor control wells. Calculated Z0-values, the standard statistical
parameter for evaluating HTS methods, are indicated below each plate.
(C) A three-dimensional scatter plot of the concentration-response curves
obtained from the library shown in (B). Percent inhibition was computed from
the no-inhibitor (0% inhibited) control and the no-enzyme (100% inhibited)
control. Concentration-response relationships are shown for inactive and
active compounds in gray and blue, respectively.
See also Table S1.
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Inhibition of the USP1/UAF1 Deubiquitinase Complexhas been shown to deubiquitinate PCNA and FANCD2 in cells
(Huang et al., 2006; Nijman et al., 2005a). PCNA ubiquitination
is central to the normal DNA damage response process in
eukaryotes (Bergink and Jentsch, 2009). Monoubiquitination of
PCNA is essential for translesion synthesis that promotes
lesion-bypass synthesis across the damaged base (Kannouche
et al., 2004; Zhuang et al., 2008). Genetic deficiency in the trans-
lesion synthesis DNA polymerase h has been linked to the
variant form of xeroderma pigmentosum (XPV). FANCD2 is an
important protein in the human Fanconi anemia (FA) pathway.
Genetic deficiency of FA proteins causes chromosomal insta-
bility and predisposition to cancer (Patel and Joenje, 2007).
One hallmark of FA patients is the hypersensitivity to DNA cross-
linking agents, such as mitomycin C, diepoxybutane, and
cisplatin. Eight FA proteins are known to form a multisubunit
complex that ubiquitinates FANCD2, which is essential for the
repair of DNA interstrand crosslinks (Alpi and Patel, 2009).
Because USP1 plays important roles in the two essential DNA
damage response pathways, it represents a promising target
for small molecule intervention to improve the efficacy of the
commonly used DNA damaging drugs by modulating cells’
ability of repairing or tolerating DNA lesions.
USP1 belongs to a class of DUBs that require an interacting
partner protein for normal enzymatic function (Reyes-Turcu
et al., 2009). Human USP1 forms a stable complex with UAF1
(Cohn et al., 2007). USP1 alone possesses low level of deubiqui-
tinating activity. Upon formation of a USP1/UAF1 complex, the
catalytic activity of USP1 is greatly stimulated. Given that many
USPs exist and function as a complex in vivo (Sowa et al.,
2009), it has become imperative to identify inhibitors against
the corresponding USP complexes. The different binding part-
ners of USPs could potentially provide the desired selectivity
against a large family of USPs that shares an otherwise
conserved catalytic site. In this study, we subjected the human
USP1/UAF1 complex to high-throughput screening and identi-
fied potent and selective inhibitors against USP1/UAF1. The
best compounds inhibit USP1/UAF1 through a noncompetitive
mechanism with submicromolar Ki values. We also demon-
strated that the USP1/UAF1 inhibitors reverse the chemoresist-
ance of non-small cell lung cancer cells to the DNA crosslinker,
cisplatin. Our findings support USP1/UAF1 as a potential target
for novel anticancer therapy and provide useful chemical tools
for understanding the role of deubiquitination in translesion
synthesis and Fanconi anemia pathway.
RESULTS
qHTS against USP1/UAF1 Using Ub-Rho as a Substrate
To date, ubiquitin-7-amino-4-methylcoumarin (Ub-AMC) has
been the substrate of choice for most DUB high-throughput
screening efforts (Colland et al., 2009; Lee et al., 2010). However,
coumarin-based fluorescence assays are limited by unfavorable
spectroscopic properties, which can lead to fluorescence arti-
facts from test compounds (Simeonov et al., 2008). To alleviate
some of the assay interference arising from fluorescent com-
pounds, we utilized the recently developed ubiquitin-rhoda-
mine110-glycine (Ub-Rho), which exhibits red-shifted fluores-
cence compared with Ub-AMC, as a substrate (Hassiepen et al.,
2007) (Figure 1A). For high-throughput screening, we used theChemistry & Biology 18, 1390–1400, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1391
Table 1. The IC50 (mM) Value of the Top FiveCompounds in Inhibiting HumanUSPsDeterminedUsing K63-LinkedDiubiquitin Substrate
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NI, no significant inhibition was observed at the highest inhibitor concentration of 114 mM.
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Inhibition of the USP1/UAF1 Deubiquitinase Complexrecombinant USP1/UAF1 complex in a 4 ml assay volume to
screen several libraries of 9525 bioactive small molecules in
qHTSmode, by testing each compound as a dilution series span-
ning the concentration range of 0.46–114 mM (see Experimental
Procedures) (Inglese et al., 2006). Consistently high Z0 factors
(above 0.8) were observed throughout the screen, indicating
a robust assay performance (Figure 1B) (Zhang et al., 1999).
The screen yielded a range of active compounds associated
with different potencies (IC50) and concentration-response curve
quality (see Figure 1C for a representative qHTS data set and see
Table S1, available online, for the top active compounds).
Secondary Validation of Active Compounds Using
an Orthogonal Diubiquitin Cleavage Assay
To validate the top actives using a more physiologically relevant
substrate, as well as to rule out false-positives acting via fluores-
cence interference, we developed an orthogonal gel-based
assay using diubiquitin (di-Ub) as a substrate to evaluate the
potency of the inhibitors. Diubiquitin as a substrate has been1392 Chemistry & Biology 18, 1390–1400, November 23, 2011 ª2011used to characterize the deubiquitinating activity of DUBs from
several families (Amerik et al., 1997; Bremm et al., 2010; Cooper
et al., 2010; Sato et al., 2008; Virdee et al., 2010). We obtained
quantitative kinetic data of USP1/UAF1 hydrolyzing K63-
and K48-linked diubiquitin using the gel-based assay. We
found that USP1/UAF1 cleaves K63-linked di-Ub substrate
with 5.5-fold higher efficiency than K48-linked di-Ub as judged
from the kcat/Km value (0.011 mM
-1 s-1 for K63-linked di-Ub;
0.002 mM-1 s-1 for K48-linked di-Ub). The kinetic values obtained
are comparable to those previously determined for several other
DUBs (Cooper et al., 2010; Virdee et al., 2010). We thus chose
K63-linked di-Ub as the substrate for quantitative secondary
assay analysis.
Using this gel assay, we independently determined the IC50
values of the top active compounds inhibiting USP1/UAF1-cata-
lyzed cleavage of the K63-linked di-Ub (Table S1). Out of the 42
compounds tested, five compounds with IC50 values ranging
from 2 to 8 mM were selected for further studies based on
potency and known compound properties (Table 1). AmongElsevier Ltd All rights reserved
Figure 2. Inhibition of USP1/UAF1 in an
Orthogonal Gel-Based Diubiquitin Assay
Dose-dependent inhibition of USP1/UAF1 activity
(left) and SDS-PAGE analysis of the cleavage of
K63-linked diubiquitin (right) in the presence of
different concentrations of pimozide (A) and
GW7647 (B).
See also Figure S1.
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Inhibition of the USP1/UAF1 Deubiquitinase Complexthem, pimozide and GW7647 were the most potent inhibitors
displaying concentration-dependent inhibition of di-Ub cleavage
with IC50 values of 2 and 5 mM, respectively (Figure 2). Three
other compounds, flupenthixol, trifluoperazine, and rottlerin,
also demonstrated potent inhibition against USP1/UAF1 with
IC50 values 8 mM or less. While the IC50 values determined using
di-Ub substrate were generally smaller compared with those
determined using Ub-Rho as a substrate, a good correlation
between the rank orders determined using the two substrates
was noted for the top active compounds.
Selectivity of the USP1/UAF1 Inhibitors against Human
USPs
We then determined the selectivity of the five compounds in
inhibiting human USPs. We selected the four well studied human
USPs, i.e., USP7, USP2, USP5, and USP8, and used them in the
diubiquitin cleavage assay. Based on the measured IC50 using
K63-linked di-Ub substrate (Table 1; Figure S1), we found that
pimozide and GW7647 are highly selective against USP1/
UAF1. Pimozide inhibits USP7 with an IC50 of 47 mM, 24-fold
higher than that measured for USP1/UAF1. No inhibition was
observed against USP2, USP5, and USP8, even with the highest
inhibitor concentration tested (114 mM). GW7647 also showed
good selectivity against USP1/UAF1. The IC50 determined for
USP7 and USP2 (44 and >114 mM, respectively) are 9 and more
than 23-fold higher than that determined for USP1/UAF1. More-
over,GW7647did not inhibit USP5andUSP8. In contrast, flupen-
thixol and trifluoperazine displayed less selectivity against
USPs. Both compounds inhibited USP7with an IC50 comparable
to that for USP1/UAF1. Nonetheless, no inhibition was observed
against USP2 and USP5. The two compounds demonstrated
weak or no inhibition against USP8. Among the top five inhibitors,
rottlerin was the least selective inhibitor. It inhibits USP1/UAF1,
USP7, USP2, and USP8 with IC50 ranging from 6 to 34 mM.
Inspection of the rottlerin structure revealed that it contains anChemistry & Biology 18, 1390–1400, November 23, 2011 ªa,b-unsaturated carbonyl group, a poten-
tial Michael acceptor that covalently
modifies active site cysteines. It should
be noted that the propensity of rottlerin
to formaggregates and inactivate enzyme
activities has also been described and
could explain its general activity across
the USPs (McGovern et al., 2003).
We also tested the top five compounds
in inhibiting USP1 alone. In the absence
of the UAF1 subunit, USP1 is a poor
enzyme and little activity was detected
in the cleavage reaction of the K63-
linked di-Ub substrate, rendering the inhi-bition measurement impossible. Thus, we used Ub-Rho as
a substrate to assess the inhibition of USP1. Pimozide,
GW7647, flupenthixol and trifluoperazine demonstrated low
level of inhibition against USP1 alone. The estimated IC50 were
at least 7- to 14-fold greater compared with the corresponding
USP1/UAF1 IC50 values determined usingUb-Rho as a substrate
(Table S2).
Similar to USP1, human USP46 forms a complex with UAF1
and the activity of USP46 is stimulated by UAF1 (Cohn et al.,
2009). Using K63-linked diubiquitin substrate, we assessed the
inhibition of USP46/UAF1 by the USP1/UAF1 inhibitors. Pimo-
zide, flupenthixol and trifluoperazine did not inhibit USP46/
UAF1 at the highest inhibitor concentrations tested (114 mM),
while low level of inhibition by GW7647 was observed (IC50 =
12 mM, Table 1).
Selectivity of the USP1/UAF1 Inhibitors against the
UCH-Family DUBs and Other Cysteine Proteases
In addition to USPs, we also assessed the selectivity of the top
five compounds in inhibiting DUBs from the ubiquitin C-terminal
hydrolase (UCH) family. Both human UCH-L1 and UCH-L3 were
tested in the inhibition assay. Because UCHs do not cleave the
diubiquitin substrate, we used Ub-Rho as a substrate for IC50
determination (Table S2). Pimozide, flupenthixol and trifluopera-
zine were poor inhibitors of UCH-L1 and UCH-L3 (IC50 >
500 mM). Similarly, GW7647 inhibited both UCHs with estimated
IC50 of greater than 200 mM. We also assessed the inhibition of
a deSUMOylase, SENP1, by the top five inhibitors using
SUMO1-AMC as a substrate. As summarized in Table S2, pimo-
zide, GW7647, flupenthixol, and trifluoperazine showed low level
of inhibition against SENP1.
The five prioritized compounds were further tested against
unrelated cysteine proteases, including human caspases and
papain (Table S2). Pimozide, flupenthixol, and trifluoperazine
showed poor inhibition of caspase-1, caspase-3, and caspase-62011 Elsevier Ltd All rights reserved 1393
Figure 3. Reversibility of Inhibition by USP1/UAF1 Inhibitors
(A) SDS-PAGE showing the diubiquitin cleavage by USP1/UAF1 that was
preincubated with different inhibitors and then rapidly diluted into assay buffer.
(B) The remaining activity of USP1/UAF1 treated with five inhibitors. The bar
graph represents mean of three independent experiments ±SD. Pimozide,
GW7647, flupenthixol, and trifluoperazine are reversible inhibitors. Rottlerin is
largely an irreversible inhibitor.
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Inhibition of the USP1/UAF1 Deubiquitinase Complex(IC50 > 250 mM). GW7647 was also a poor inhibitor of caspase-3
(IC50 > 250 mM), but inhibited caspase-1 and caspase-6 with IC50
values of 42 mM and 21 mM, respectively. Pimozide and
flupenthixol did not inhibit papain (IC50 > 250 mM). GW7647
and trifluoperazine demonstrated weak inhibition against papain
with IC50 values around 130 mM. In comparison, rottlerin inhibited
all three caspases, as well as papain with an effect similar to
that displayed against the USPs (IC50 ranging between 5 and
45 mM).
Reversible USP1/UAF1 Inhibitors
Reversibility of the inhibition of USP1/UAF1 by the top five
compoundswas tested using a protocol developed by Copeland
and coworkers (Copeland, 2005). USP1/UAF1 (10 mM) was incu-
batedwith the compound applied at a concentration ten times its
IC50. Upon rapid dilution (100-fold) into the assay buffer, the
incubated USP1/UAF1-inhibitor mixture was assayed for enzy-
matic activity. Our results indicated that pimozide, GW7647,
flupenthixol, and trifluoperazine were largely reversible inhibitors
because USP1/UAF1 treated with these inhibitors exhibited
rapid recovery of activity upon dilution. The measured activity
of USP1/UAF1 following dilution was close to that determined
in the control reaction usingDMSO solvent (Figure 3). In contrast,
rottlerin was an irreversible inhibitor of USP1/UAF1 with only
18% enzymatic activity recovered following the same incuba-
tion-dilution protocol.1394 Chemistry & Biology 18, 1390–1400, November 23, 2011 ª2011Pimozide and GW7647 Inhibit USP1/UAF1
by a Noncompetitive Mechanism
The inhibition mechanism of pimozide and GW7647 was
assessed bymeasuring the steady-state rate constants at varied
inhibitor concentrations using K63-linked di-Ub as a substrate.
The Lineweaver-Burk plots for both pimozide and GW7647 (Fig-
ure 4) indicate a noncompetitive inhibition mechanism. The
measured inhibition constants (Ki) for pimozide and GW7647
are 0.5 and 0.7 mM, respectively. These observations suggest
that both pimozide and GW7647 bind at a site other than the
active site of USP1/UAF1. We can also infer that both inhibitors
bind the enzyme and enzyme substrate complex with equal
affinity. We ruled out that pimozide and GW7647 inhibited
USP1/UAF1 by disrupting the protein-protein interaction within
the complex. Our native gel electrophoresis following the incuba-
tion of USP1/UAF1 with pimozide or GW7647 (up to 10 3 IC50)
showed no dissociation of the USP1/UAF1 complex (Figure S2).
USP1/UAF1 Inhibitors Sensitize Cisplatin-Resistant
NSCLC Cells to Cisplatin Killing
We determined the viability of the cisplatin-resistant human
non-small cell lung cancer (NSCLC) cells (H596, NCI) treated
with a combination of cisplatin and the USP1/UAF1 inhibitors,
pimozide or GW7647. Cisplatin alone killed human H596 cells
with an EC50 of 8.1 mM (Figures 5A and 5B), in concordance
with a previous report (Zeng-Rong et al., 1995). Pimozide and
GW7647 alone demonstrated modest cytotoxicity against
H596 cells with EC50 of 21 and 26 mM, respectively. We then
assessed the cytotoxicity of cisplatin in combination with
USP1/UAF1 inhibitors by following the method of Chou-Talalay
(Chou et al., 1994; Zastre et al., 2007). Specifically, wemeasured
the viability of NCI H596 cells treated with a combination of
cisplatin and USP1/UAF1 inhibitor (pimozide or GW7647) at
a fixed molar ratio of 1:1 or 1:4 (Figures 5A and 5B). EC50 were
obtained for each combination. A combination of cisplatin and
pimozide at a ratio of 1:1 and 1:4 significantly enhanced the cyto-
toxicity of cisplatin as judged from the EC50 values of 5.1 and
2.8 mM, respectively. For the cisplatin and pimozide combination
at a ratio of 1:4, the EC50 of 2.8 mM approaches the EC50 of
1.2 mM determined for the cisplatin-sensitive NSCLC H460 cell
line (Figures S3A and S3B). Enhanced cytotoxicity was also
observed for H596 cells treated with a combination of cisplatin
and GW7647 at a ratio of 1:4 with a measured EC50 of 4.3 mM.
We next determined the nature of the interactions between
cisplatin and theUSP1/UAF1 inhibitors. To this end, thecell killing
curves were analyzed using the program CalcuSyn as described
previously (Chou, 2010; Radujkovic et al., 2005; Shanks et al.,
2005; Zastre et al., 2007). The resulting combination indexes
(CI) were plotted against the fraction affected by the dose (Fa).
A combination index (CI) smaller than one indicates synergistic
effect, while a CI equal to one indicates additive effect (Chou,
2010). As shown in Figure 5C, a synergistic effect was observed
for the combination of cisplatin and pimozide at a ratio of 1:1 and
1:4, and for cisplatin and GW7647 at a ratio of 1:4.
We also tested the cisplatin-sensitive human non-small cell
lung cancer (NSCLC) cells (H460, NCI). Interestingly, a combina-
tion of cisplatin and pimozide/GW7647 at a ratio of 1:1 and 1:4
did not further increase the cytotoxicity of cisplatin (Figures
S3A and S3B).Elsevier Ltd All rights reserved
Figure 4. Inhibition Mechanism of Pimozide and GW7647
Lineweaver-Burk plots of USP1/UAF1-catalyzed hydrolysis of diubiquitin in the presence of 0 (square), 0.5 (circle), 1 (triangle), 2 (diamond) mM of pimozide (A) or
GW7647 (B). The inset shows the plot of the slopes obtained from the Lineweaver-Burk plots against the inhibitor concentrations.
See also Figure S2.
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Inhibition of the USP1/UAF1 Deubiquitinase ComplexPimozide and GW7647 Inactivate USP1/UAF1 in Cells
USP1/UAF1 was shown to deubiquitinate both PCNA and
FANCD2 in response to DNA damage (Cohn et al., 2007; HuangFigure 5. Cytotoxicity of Cisplatin, Pimozide, and GW7647 Tested as a
(H596)
(A) Cytotoxicity of cisplatin alone (green diamond), pimozide (blue triangle), or a
square).
(B) Cytotoxicity of cisplatin alone (green diamond), GW7647 (blue triangle), or a
square). Cell viability determined with equal volume of vehicle was treated as 10
(C) Combination index (CI) for treating H596 cells with a combination of cisplatin a
pimozide at ratios of 1:1 (filled blue triangle), 1:4 (filled blue circle) or with a combin
circle). The combination indices were calculated using software CalcuSyn for each
horizontal line in the figure represents a combination index = 1. See also Figure
Chemistry & Biology 18, 1390–140et al., 2006). In order to demonstrate that pimozide and GW7647
inhibit the USP1/UAF1 activity in cells, we developed an assay to
determine the levels of Ub-PCNA or Ub-FANCD2 in cells treatedSingle Agent or in Combination on Cisplatin-Resistant NSCLC Cells
combination of cisplatin and pimozide at ratios of 1:1 (red circle), 1:4 (black
combination of cisplatin and GW7647 at ratios of 1:1 (red circle), 1:4 (black
0%. Data are mean of three independent experiments ±SD.
nd pimozide or GW7647. Cells were treated with a combination of cisplatin and
ation of cisplatin and GW7647 at ratios of 1:1 (open red triangle), 1:4 (open red
combination and plotted against the fraction of cells affected (Fa). The dashed
S3.
0, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1395
Figure 6. Treatment of Human Cells by USP1/UAF1 Inhibitors Leads to the Increase in PCNA and FANCD2 Monoubiquitination
HEK293T cells were treated with cisplatin, USP1/UAF1 inhibitors (pimozide or GW7647), or a combination of cisplatin and pimozide or GW7647. The cells treated
with the vehicle (DMSO) were used as control. Cell lysate was analyzed bywestern blotting using anti-PCNA antibody (A) or anti-FANCD2 antibody (B). The PCNA
and Ub-PCNA bands were quantified and the percentage of monoubiquitinated PCNA is reported in the bottom panel. The data presented here were an average
of three independent experiments. The percentage of monoubiquitinated FANCD2 was determined in the same way. See also Figure S4.
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Inhibition of the USP1/UAF1 Deubiquitinase Complexwith cisplatin, pimozide/GW7647 or a combination of cisplatin
and pimozide/GW7647. When HEK293T cells were treated with
cisplatin alone, a small, but significant, percent of Ub-PCNA was
detected, agreeing with observations made in several different
human cell lines (Albertella et al., 2005; Brun et al., 2010; Terai
et al., 2010). When the cells were incubated with a combination
of cisplatin with pimozide or GW7647, the percentage of Ub-
PCNA more than tripled (Figure 6A). Notably, when the cells
were treated with pimozide or GW7647 alone, a significant
increase in monoubiquitination of PCNA was also observed,
albeit the increase was lower than that of the cells treated with
cisplatin in combination with pimozide or GW7647. Similar
observation was alsomade for the cisplatin-resistant and -sensi-
tive NSCLC cells (Figures S4A and S4B).
We also assessed the effect of USP1/UAF1 inhibitors on the
cellular Ub-FANCD2 level in HEK293T cells. Using an anti-
FANCD2 antibody, we observed that approximately 25% of
FANCD2 were monoubiquitinated when cells were treated with
cisplatin alone. Similar to PCNA monoubiquitination, treatment
of HEK293T cells with cisplatin in combination with pimozide
or GW7647 led to increase in the level of monoubiquitinated
FANCD2 to 40%. Treatment of HEK293T cells with pimozide or
GW7647 led to increase in Ub-FANCD2 level, but to an extent
lower than that of the cells treated with the combination of
cisplatin with pimozide or GW7647.
We further investigated the effect of pimozide and GW7647 on
histone H2A monoubiquitination, a prevalent histone modifica-
tion in mammalian cells. Treating the HEK293T cells with pimo-1396 Chemistry & Biology 18, 1390–1400, November 23, 2011 ª2011zide or GW7647 had no effect on the level of Ub-H2A either in
the presence or absence of cisplatin (Figure S4C).
DISCUSSION
Conventional protease inhibitor discovery relies on small mole-
cules that bind to the protease active site. This approach has
garnered some success, especially when structural information
of the protease is available. However, it faces challenges due
to the common problem of overlapping activity or lack of speci-
ficity of the active site-targeting protease inhibitors. In recent
years there has been increasing realization that both selectivity
and potency of protease inhibitors can be potentially achieved
by targeting the protease exosite or allosteric site (Drag and Sal-
vesen, 2010; Kornacker et al., 2005; Scheer et al., 2006).
One emerging feature of DUBs and the related deSUMOylases
is that the efficient catalysis requires extensive interactions in the
enzyme exosite. This is reflected by the observation that the
substrate based on the linear epitope recognized by the active
site of DUBs or deSUMOylases can only be cleaved at a rate
five to six orders of magnitude lower compared with substrate
that contains a complete ubiquitin or SUMO moiety (Drag and
Salvesen, 2010). Thus, targeting the DUB exosite is a promising
alternative strategy for developing DUB inhibitors. Moreover,
many DUBs are regulated by specific interaction with their
protein partner (Reyes-Turcu et al., 2009). For some DUBs, this
interaction is required for their catalytic activity. Although the
detailed mechanism of such regulation remains to be elucidated,Elsevier Ltd All rights reserved
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Inhibition of the USP1/UAF1 Deubiquitinase Complexallosteric regulation likely plays a central role in modulating the
DUB enzymatic activity. Therefore, inhibitor discovery by target-
ing DUBs at sites other than the active site should serve to
validate the new paradigm of protease inhibitor development.
High-throughput screening, being largely amechanistically unbi-
ased approach, carries an advantage over rational inhibitor
design that targets solely the active site, and as such is expected
to allow the identification of inhibitors targeting the exosite or
allosteric site.
In this study, we identified USP1/UAF1 inhibitors, pimozide
and GW7647, through quantitative high-throughput screening
against a collection of 9525 bioactive molecules. Our kinetic
analyses revealed noncompetitive mechanism for both inhibi-
tors, suggesting that both compounds bind at a site different
from the active site. Interestingly, both compounds are poor
inhibitors of USP1 alone. This again supports the notion that
both inhibitors bind outside the USP1 active site and may form
the basis for the selectivity of pimozide and GW7647 in inhibiting
USP1/UAF1 among the group of human USPs tested. We also
confirmed that pimozide and GW7647 are both reversible inhib-
itors. Different from a previously reported USP7 inhibitor that
acts as an uncompetitive inhibitor (Colland et al., 2009), pimozide
and GW7647 appear to bind to both the enzyme-substrate
complex and the free enzyme. The inhibition mechanism of
another recently reported inhibitor against USP14 has not been
rigorously studied, albeit a competitive mechanism was sug-
gested (Lee et al., 2010).
We found that both pimozide and GW7647 were more potent
inhibitors against USP1/UAF1 when the inhibition was assayed
using K63-linked diubiquitin substrate as compared with Ub-
Rho as a substrate. This raised the interesting possibility that
the different binding modes of diubiquitin and Ub-Rho to
USP1/UAF1 may affect the potency of the noncompetitive inhib-
itor. Recent structure determination of the K63-linked diubiquitin
bound to AMSH-LP revealed specific interactions between the
proximal ubiquitin and the DUB catalytic core as well as an
inserted motif (Sato et al., 2008). Thus, it is possible that pimo-
zide and GW7647 bind to a site on USP1/UAF1 that partially
overlaps with the proximal ubiquitin binding site, thus contrib-
uting to the stronger inhibition observed for diubiquitin as
a substrate. Another possibility is that pimozide and GW7647
may bind to an allosteric site that influences the binding of
proximal ubiquitin. It should be noted that we used K63-linked
di-Ub as a substrate for selectivity assay because USP1/UAF1
cleaves K63-linked di-Ubmore efficiently than K48-linked di-Ub.
However, we do not rule out that the identified inhibitors may
inhibit USPs with varied potency when a ubiquitin chain with
different linkages is tested as a substrate.
Many anticancer drugs are DNA crosslinkers that exert their
effects by damaging the genomic DNA of cancer cells, which
in turn triggers apoptosis of the cells. Cisplatin and other plat-
inum-based anticancer drugs act by crosslinking the genomic
DNA. Despite considerable success in treating human cancers,
the effectiveness of cisplatin and other platinum drugs in clinics
has been limited by the resistance that cancer cells developed
during the course of therapy. Therefore, overcoming cancer
cells’ resistance to cisplatin and other platinum drugs by combi-
nation therapies is a promising strategy for treating cancer.
Cisplatin is known to elicit both intrastrand and interstrandChemistry & Biology 18, 1390–140DNA crosslinks, with the intrastrand crosslink being more prev-
alent. Previous studies have linked the Fanconi anemia pathway
to cellular repair of interstrand DNA crosslinks caused by chem-
ical crosslinker such as cisplatin, albeit the exact mechanism of
this repair process remains to be fully elucidated (Wang, 2007).
On the other hand, translesion synthesis has been linked to cell’s
ability to tolerate both cisplatin-induced intrastrand and inter-
strand DNA crosslinks (Hicks et al., 2010; Sonoda et al., 2003;
Wu et al., 2004). Furthermore, translesion synthesis and Fanconi
anemia pathway are closely linked. Recent studies revealed that
K164 PCNA monoubiquitination is required to recruit FANCL to
the chromatin structure and stimulate FANCL-catalyzed ubiq-
uitination of FANCD2 and FANCI (Geng et al., 2010).
The exact role of deubiquitination of PCNA and FANCD2 by
USP1/UAF1 in human DNA damage response remains to be
elucidated. Knocking down USP1 in human HEK293 cells was
shown to protect cells fromMMC-induced chromosomal aberra-
tions (Nijman et al., 2005a). Nonetheless, in chicken DT40
cells, deletion of USP1 led to increased sensitivity of DT40 cells
to cisplatin (Oestergaard et al., 2007). Similar observation
was made in USP1 knockout mouse (Kim et al., 2009). A
unified view of the effect of inhibiting USP1 cellular activity on
vertebrate DNA damage response has not been obtained. In
the current study, we demonstrated that inhibiting the cellular
activity of USP1/UAF1 by small molecule inhibitors sensitized
human cisplatin-resistant NSCLC H596 cells to DNA crosslinker
cisplatin.Wealsoobserved sensitization ofH596cells to cisplatin
when treated in combinationwith siRNA targeting USP1, albeit to
a less extent under our assay condition (Figure S3C). Compared
with the siRNA approach, the small-molecule inhibitor allowed us
to probe the cellular function of USP1/UAF1 without perturbing
the level of USP1/UAF1 complex in human cells. This is particu-
larly desirable given the recent realization that a vast interaction
network exists between USPs andmany of their protein partners
in cells (Sowa et al., 2009). Notably, we did not observe further
sensitization of cisplatin-sensitive NSCLC H460 cell lines to
cisplatin upon treatment with pimozide and GW7647. Our obser-
vations support the notion that USP1/UAF1 is involved in the
NSCLC cell’s resistance to cisplatin-induced DNA damage.
We demonstrated the on-target effect of the USP1/UAF1
inhibitors in human cells in disrupting the USP1-catalyzed deubi-
quitination of PCNA and FANCD2, but not the deubiquitination of
histone H2A. We observed that treatment of cells with the USP1/
UAF1 inhibitor alone led to increase in the levels of Ub-PCNA and
Ub-FANCD2. This observation suggests that PCNA and
FANCD2 undergo dynamic ubiquitination and deubiquitination
even in the absence of exogenous DNA damaging events.
The USP1/UAF1 inhibitors identified in this work are bioactive
molecules. Pimozide, a diphenylbutylpiperidine derivative, is
also known for its neuroleptic property in treating chronic schizo-
phrenic patients (Opler and Feinberg, 1991). However, evidence
has suggested that the pharmacological activity of pimozide
may not be limited to its neuroleptic function. It has been
reported that pimozide inhibits the proliferation of human
melanoma and breast cancer cells (Neifeld et al., 1983; Strobl
et al., 1990). In this study, we showed that pimozide is a potent
inhibitor of a human DUB, USP1/UAF1, and provided insight
into the molecular basis for the antineoplastic activity of pimo-
zide. GW7647, another potent USP1/UAF1 inhibitor, was initially0, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1397
Chemistry & Biology
Inhibition of the USP1/UAF1 Deubiquitinase Complexidentified as an agonist of human peroxisome proliferator-acti-
vated receptor-a (PPARa), a ligand-activated transcription factor
involved in the regulation of lipid homeostasis (Brown et al.,
2001). So far, no cytocidal activity against human cell lines has
been reported for GW7647. Our studies revealed a modest
synergistic effect of GW7647 in killing human cisplatin-resistant
NCSLC cells when combined with cisplatin. Taken together, the
studies presented here revealed the potential new use of two
pharmacologically active agents.
A desirable feature of therapeutics to be used in combination
with DNA crosslinking drugs is the synergistic interaction
between the compound and DNA crosslinkers. The synergy
between cisplatin and USP1/UAF1 inhibitors was demonstrated
in preventing the proliferation of cisplatin-resistant NSCLC cells.
Our results validated USP1/UAF1 as a potential target for devel-
oping novel therapeutics for combination therapy to overcome
cancer cells’ resistance to cisplatin and possibly other DNA
crosslinkers.
Lastly USP1/UAF1 represents a group of USPs that were
recently found to specifically interact with WD40 repeat proteins
(Sowa et al., 2009). The present identification of selective,
noncompetitive inhibitors against the USP1/UAF1 complex
represents the first example of targeting the USP/WD40 repeat
protein complex for inhibitor discovery. The newly identified
USP1/UAF1 inhibitors should also serve as valuable chemical
tools for studying the human DNA damage response that
involves translesion synthesis and Fanconi anemia pathway.
SIGNIFICANCE
In recent years, the noncanonical function of ubiquitin has
been shown to be important for a number of cellular pro-
cesses, including membrane trafficking, innate immunity,
kinase signaling, chromatin dynamics, and DNA damage
response. Recent discoveries of the essential regulatory
roles of ubiquitin in DNA damage response have fueled
the rapid progress in this important research area. Two
major DNA damage response pathways, namely, translesion
synthesis (TLS) and Fanconi anemia (FA), are at the center of
the research effort in understanding the novel function of
ubiquitin. Moreover, the two pathways also provide prom-
ising targets for novel anticancer therapies. USP1/UAF1,
as a prototype of a group of USP/WD40 repeat protein com-
plexes, has attracted increasing attention for small-mole-
cule inhibitor discovery. However, no inhibitors of USP1/
UAF1 have been reported. The lack of small-molecule inhib-
itors of ubiquitin-specific proteases (USPs) in general has
hampered the progress in understanding and exploiting
this large family of DUBs. In this work we discovered
potent, and cell-active inhibitors of the USP1/UAF1 complex
through quantitative high-throughput screening (qHTS).
This work demonstrated the feasibility of selective inhibition
of the deubiquitinase complex that belongs to the wide-
spread USP/WD40 repeat protein family. The therapeutic
potential of inhibiting USP1/UAF1 was demonstrated by the
observation that the USP1/UAF1 inhibitors can reverse
the chemoresistance of non-small cell lung cancer cells to
the chemotherapeutic agent, cisplatin. The current USP1/
UAF1 inhibitors are also valuable chemical tool for under-1398 Chemistry & Biology 18, 1390–1400, November 23, 2011 ª2011standing the role of deubiquitination in translesion synthesis
and Fanconi anemia pathway.EXPERIMENTAL PROCEDURES
Quantitative High-Throughput Screen
USP1/UAF1 activity was monitored in a fluorometric assay, using ubiquitin-
rhodamine110-glycine (Ub-Rho; Boston Biochem). Enzymatic reactions
were conducted in an assay buffer (50 mM HEPES [pH 7.8], 0.5 mM EDTA,
100 mM NaCl, 1 mM TCEP, 0.1 mg/ml BSA, and 0.01% Tween-20) that
contained 1 nM USP1/UAF1. Each individual compound was tested at five
concentrations in the range of 0.46–114 mM. The plates were incubated for
15 min to attain equilibrium, and then the enzymatic reaction was initiated
by dispensing 1 ml of Ub-Rho solution (150 nM final concentration). The plates
were directly transferred to a ViewLux high-throughput CCD imager
(PerkinElmer), where kinetic measurements of rhodamine fluorescence were
acquired using a 480 nm excitation/540 nm emission filter set. The change
in fluorescence intensity over a 5 min reaction period (typically associated
with less than 10% substrate conversion) was normalized against no-inhibitor
and no-enzyme controls and the resulting percent inhibition data were fitted
to a sigmoidal dose response using a four-parameter Hill equation (Southall
et al., 2009).
Assay Inhibition of USP1/UAF1 Using K63-Linked di-Ub
as a Substrate
Inhibitors at varied concentrations (0.08–114 mM) were added to the assay
solution containing 100 nM USP1/UAF1, 2 mM K63-linked diubiquitin (Boston
Biochem) in a buffer containing 50 mM HEPES (pH 7.8), 0.1 mg/ml BSA,
0.5 mM EDTA, and 1 mM DTT. The reaction was allowed for 1 hr at 37C,
and quenched by the addition of Laemmli sample buffer. The reaction
product was separated on a 20% denaturing SDS-PAGE gel and stained
with Coomassie blue. The intensity of the individual diubiquitin and monoubi-
quitin bands were quantified using Quantity One software (Bio-Rad). The
enzyme activity was normalized against no-inhibitor control and plotted
against inhibitor concentration. The IC50 value was determined by fitting
the dose response curve to Equation 1 using GraphPad Prism (GraphPad
Software).
Y =Y0 +
Ymax  Y0
1+ 10XLog IC50
where X = Log[inhibitor]; Y is the enzyme activity in percent relative to control.
GraphPad Prism reports the standard error of LogIC50, but not of IC50.
Cytotoxicity Assay
Human non-small cell lung cancer (NSCLC) cell line H596 and H460 were
purchased from American Type Culture Collection. H596 and H460 cells
were grown in RPMI 1640 medium (ATCC) supplemented with 10% FBS
(ATCC) at 37C and 5% CO2. In cytotoxicity assay, 53 10
3 cells were seeded
in each well of the 96-well plate and grown for 24 hr in humidified incubator.
H596 and H460 cells were first treated with cisplatin, pimozide or GW7647
individually for 48 hr to determine the EC50 of each compound. In combination
assay, cisplatin was dissolved in saline solution; pimozide and GW7647 were
dissolved in DMSO. Equal volume of above solutions was added to each well
and cells were incubated for 48 hr. The cells treated with equal volume of
DMSO and saline were used as control and designated as 100% viability.
Ten microliters of CCK-8 solution (Dojindo Molecular Technologies) was
added to each well following the treatment to determine the cell viability where
the tetrazolium salt (WST-8) was reduced by dehydrogenases in cells to give
a yellow-colored product (formazan). Plates were incubated for 3 hr at 37C
and the absorbance at 450 nm was measured using a microplate reader
(PerkinElmer). Dose-response curves were generated and EC50 value was
obtained by fitting the data to Equation 2 using GraphPad Prism.
Y =
100
1+ 10ðLog EC50XÞ$n
where X = Log[inhibitor]; Y is cell viability in percent relative to the control; n is
Hillslope.Elsevier Ltd All rights reserved
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and the USP1/UAF1 Inhibitor
To determinewhether a combination of cisplatin and the USP1/UAF1 inhibitors
exert the effect synergistically or additively, cisplatin and USP1/UAF1 inhibitor
(pimozide or GW7647) were combined in fixed molar ratios of 1:1 and 1:4. The
cell viability was determined in a range of compound concentrations as
described above. To calculate the combination index, the dose-response
curves were analyzed using CalcuSyn (Biosoft), which is based on the
median-effect principle developed by Chou and Talalay (1984). The combina-
tion index (CI) was determined for the fraction of cells affected (Fa) following
addition of the fixed ratios of cisplatin and USP1/UAF1 inhibitor.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, two tables, and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.chembiol.2011.08.014.
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